125 related articles for article (PubMed ID: 8883412)
1. Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens.
Touitou Y; Bogdan A; Lévi F; Benavides M; Auzéby A
Br J Cancer; 1996 Oct; 74(8):1248-52. PubMed ID: 8883412
[TBL] [Abstract][Full Text] [Related]
2. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
4. [1959-1999: from serum markers to 18-FDG in oncology. The experience of the René-Huguenin Center].
Pecking AP; Mechelany-Corone C; Pichon MF
Pathol Biol (Paris); 2000 Nov; 48(9):819-24. PubMed ID: 11141917
[TBL] [Abstract][Full Text] [Related]
5. Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery.
Cash E; Sephton SE; Chagpar AB; Spiegel D; Rebholz WN; Zimmaro LA; Tillie JM; Dhabhar FS
Brain Behav Immun; 2015 Aug; 48():102-14. PubMed ID: 25728235
[TBL] [Abstract][Full Text] [Related]
6. Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors.
Touitou Y; Lévi F; Bogdan A; Benavides M; Bailleul F; Misset JL
J Cancer Res Clin Oncol; 1995; 121(3):181-8. PubMed ID: 7713990
[TBL] [Abstract][Full Text] [Related]
7. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
8. Serum carcinoembryonic antigen, cancer antigen 125, cancer antigen 15-3, squamous cell carcinoma, and tumor-associated trypsin inhibitor concentrations during healthy pregnancy.
Schlageter MH; Larghero J; Cassinat B; Toubert ME; Borschneck C; Rain JD
Clin Chem; 1998 Sep; 44(9):1995-8. PubMed ID: 9732993
[No Abstract] [Full Text] [Related]
9. BR-MA, OM-MA, GI-MA and CEA: clinical evaluation using the IMMULITE analyzer.
van Dalen A
Tumour Biol; 1999; 20(3):117-29. PubMed ID: 10213919
[TBL] [Abstract][Full Text] [Related]
10. Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate.
Murray A; Clinton O; Earl H; Price M; Moore A
Eur J Cancer; 1995 Sep; 31A(10):1605-10. PubMed ID: 7488409
[TBL] [Abstract][Full Text] [Related]
11. Determination of whole body circadian phase in lung cancer patients: melatonin vs. cortisol.
Mazzoccoli G; Giuliani F; Sothern RB
Cancer Epidemiol; 2012 Feb; 36(1):e46-53. PubMed ID: 22000330
[TBL] [Abstract][Full Text] [Related]
12. Circadian rhythms of tumor markers in breast cancer patients.
Touitou Y; Bailleul F; Lévi F; Bogdan A; Touitou C; Metzger G; Mechkouri M
Prog Clin Biol Res; 1990; 341A():59-66. PubMed ID: 2217278
[No Abstract] [Full Text] [Related]
13. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer.
Nicolini A; Carpi A; Ferrari P; Anselmi L; Spinelli C; Conte M; Miccoli P
Br J Cancer; 2000 Dec; 83(11):1412-7. PubMed ID: 11076646
[TBL] [Abstract][Full Text] [Related]
14. Possible linkage between the ability to change the period (tau) of the prolactin and cortisol rhythms in women and breast cancer risk.
Lewy H; Haus E; Ashkenazi IE
Chronobiol Int; 2007; 24(2):365-81. PubMed ID: 17453854
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour markers in breast cancer.
Seregni E; Coli A; Mazzucca N;
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S15-22. PubMed ID: 15127239
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
[TBL] [Abstract][Full Text] [Related]
18. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
20. Elevated CA125 in breast cancer--A sign of advanced disease.
Norum LF; Erikstein B; Nustad K
Tumour Biol; 2001; 22(4):223-8. PubMed ID: 11399947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
